Prognostic value of GST-pi expression in diffuse large B-cell lymphomas

Area of Science:

• Oncology
• Biochemistry
• Immunohistochemistry

Background:

• The glutathione system is implicated in resistance to chemotherapy agents like alkylating agents and anthracyclines.
• Glutathione S-transferase pi (GST-pi) is a key enzyme in the glutathione system, studied for its role in drug resistance.

Purpose of the Study:

• To investigate the relationship between GST-pi expression in tumor cells and patient outcomes in diffuse large B-cell lymphoma (DLBCL).
• To determine if GST-pi expression is an independent prognostic factor in DLBCL.

Main Methods:

• Immunohistochemistry was used to analyze GST-pi expression in tumor cells from 69 DLBCL cases.
• Patients were categorized with low (<50% stained cells) or high (>/=50% stained cells) GST-pi expression.
• Outcomes, including complete remission (CR), freedom from progression (FFP), and survival, were analyzed over a median follow-up of 58 months.

Main Results:

• High GST-pi expression was significantly correlated with a lower probability of achieving complete remission (CR).
• Patients with high GST-pi expression had worse 5-year freedom from progression (FFP) and a trend towards lower survival.
• GST-pi expression was found to be an independent prognostic factor for FFP in multivariate analysis, even when considering the International Prognostic Index (IPI).

Conclusions:

• GST-pi expression is a significant prognostic marker in DLBCL.
• High GST-pi levels indicate a poorer prognosis, independent of established prognostic factors like the IPI.
• Targeting the glutathione system or GST-pi may offer therapeutic strategies for DLBCL.